## REBLOZYL<sup>®</sup> AUTHORIZATION TO INJECT **BETA(β)-THALASSEMIA**

This form should be completed ONLY in one of the following scenarios:


- Per your preference indicated in the Enrolment form
- After a period of 8 dosing cycles (24 weeks)
- Upon a change of dose

## The completed form MUST be sent to the Patient Support Program for REBLOZYL at least 3 business days prior to next injection

Program Patient ID:		Ρατ	teint Initials:	
Patient Date of Birth (DD/MONTH/YYYY):				
Section 1: Treatment Information This section is to be completed by the Patient Support Program for REBLOZYL.				
Next scheduled injection	Date (DD/MONTH/YYYY):		Time (24HR):	
Previous injection	Date (DD/MONTH/YYYY):	Dose level (mg/kg):	Cycle number:	
First injection (start date)	Date (DD/MONTH/YYYY):			
Patient weight	Weight taken from most recent post-injection report Weight (kg):		Date (DD/MONTH/YYYY):	
Physician information	Last name: First name: Location: Pharmacy:			
Section 2: Prescription This section is to be completed per your preference indicated in the Enrolment form, after a period of 8 dosing cycles (24 weeks), or upon a change of dose.				
Patient information				
Last name: First name:				
Home address:				
City:	Province: Postal code:			
Allergies and/or other medication(s) or relevant medical information:				
REBLOZYL (luspatercept for injection) dose level*	<ul> <li>□ 1.25 mg/kg</li> <li>□ 1.0 mg/kg</li> <li>□ 0.8 mg/kg</li> <li>□ 0.6 mg/kg</li> <li>□ No dose required (due to hemoglobin level that is: ≥115 g/L and not influenced by recent transfusion).</li> </ul>			
Prescription valid for a maximum of 8 dosing cycles				
Otherwise, please specify:				
* REBLOZYL injections are recommended once every 3 weeks by subcutaneous injection. The dosage indicated on this form will be applied for a maximum of 8 cycles, unless otherwise specified. Please see the Product Monograph for complete dosing and administration instructions.				
Medical license number:				
By signing below, I acknowledge that I am responsible for informing the Patient Support Program for REBLOZYL of any changes to the prescribed REBLOZYL dosing regimen appropriate for this patient after reviewing and assessing the patient's blood tests prior to each injection. In the absence of any reported changes from Physician to Program, such as adjusting the patient dose or discontinuing treatment based on how the patient responds to REBLOZYL, the Program should continue to dose the patient in accordance with my most recent instructions.				
Signature of Referring Physician/Hematologist:		Date	Date (DD/MONTH/YYYY):	

## Patient Support Program for REBLOZYL: Phone: 1-833-951-2482 Fax: 1-833-951-2483

Reference: REBLOZYL Product Monograph. Celgene Inc.



Patient Support Program > Your patient. Our commitment. REBLOZYL and the REBLOZYL logo are registered trademarks of Celgene Corporation used under license by Celgene Inc. ©2023 Celgene Corporation 2007-CA-2300007E



